Member Info for dafad

https://drive.google.com/file/d/1YFFKaLQX7VxdJ8WUb8gFsz9aG-8dSxza/view

at 3.97 at close

Anglo American Platinum Ltd. said on Monday that it sold its 50% interest in the Kroondal and Marikana Pool-and-share Agreements to Sibanye-Stillwater Ltd. for 1 rand (6 cents).

The South African miner said the conditional transaction will extend the project's life-of-mine, and that Sibanye will take over all closure costs and rehabilitation liabilities.

"By enabling Kroondal to mine through the boundary at Sibanye-Stillwater's Rustenburg operations, we will extract our attributable share of the Kroondal reserves more quickly and efficiently than under the previous mine plan, unlocking greater value for Anglo American Platinum and Sibanye-Stillwater," the company said.

Abstract
SARS-CoV-2 infection is benign in most individuals but, in ˜10% of cases, it triggers hypoxemic COVID-19 pneumonia, which becomes critical in ˜3% of cases. The ensuing risk of death (˜1%) doubles every five years from childhood onward and is ˜1.5 times greater in men than in women. What are the molecular and cellular determinants of critical COVID-19 pneumonia? Inborn errors of type I IFNs, including autosomal TLR3 and X-linked TLR7 deficiencies, are found in ˜1-5% of patients with critical pneumonia under 60 years old, and a lower proportion in older patients. Pre-existing autoantibodies neutralizing IFN-a, –ß, and/or –?, which are more common in men than in women, are found in ˜15-20% of patients with critical pneumonia over 70 years old, and a lower proportion in younger patients. Thus, at least 15% of cases of critical COVID-19 pneumonia can apparently be explained. The TLR3- and TLR7-dependent production of type I IFNs by respiratory epithelial cells and plasmacytoid dendritic cells, respectively, is essential for host defense against SARS-CoV-2. In ways that can depend on age and sex, insufficient type I IFN immunity in the respiratory tract during the first few days of infection may account for the spread of the virus, leading to pulmonary and systemic inflammation.

and another
https://www.nature.com/articles/s41586-022-04447-0

is that no one knows whenthe trial, results will be out or more to the point what those trial results will be.
So imho these shares were bought having been advised by the Nomad that all was above board,results could come at
any time

Southampton, UK - 28 January 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, announces that it was notified on 27 January 2022 that the spouse of Brooke Clarke, Senior Vice President, Head of Communications and PDMR, had purchased 8,520 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at an average price of 189.717p.



Following the purchase, the spouse of Brooke Clarke has a total interest over 8,520 Ordinary Shares, representing 0.004 per cent. of the Company's issued share capital.

Electronic Arts (NASDAQ: EA) shareholders are in for a bumpy trading week ahead. The video game giant, whose stock has trailed the market over the past year, will report fiscal 2022 third-quarter earnings on Feb. 1.

Investors are hoping that the video game publisher has good news to reveal about demand trends and profitability through late 2021. The outlook for the full fiscal year might receive a significant update, too, depending on how well its latest game launches, like the latest in the Battlefield franchise, have done.

With that big picture in mind, let's look at a few metrics to watch when EA reports earnings on Tuesday.

https://www.exchangewire.com/blog/2022/01/27/cavai-azerion-alliance-to-amplify-conversational-advertising-to-more-european-markets/

Update on Feb 1st last year,Feb 11th previous

My bet is something next week

Interesting from 32min 30 sec,Not sure how old the video is

https://www.youtube.com/watch?v=rmcKUWd0wks

Ignore previous post

Interesting from today's Sunday Times

Chronic Respiratory Disease!!

Rest of article behind paywall

Https://www.thetimes.co.uk/article/covid-blueprint-to-transform-new-drugs-for-millions-bbjpn2g69

Covid blueprint to transform new drugs for millions
Sir Martin Landray’s organisation will run low-cost, stripped-back clinical trials for the most common but often neglected diseases
Sir Martin Landray’s organisation will run low-cost, stripped-back clinical trials for the most common but often neglected diseases

The scientist who identified the first life-saving Covid drug will launch a project tomorrow to transform treatments for heart disease, dementia and arthritis.

Sir Martin Landray was the architect of the world-leading Recovery trial which identified the cheap steroid dexamethasone as an effective treatment.
His new not-for-profit organisation, Protas, will run low-cost, stripped-back clinical trials for the most common but often neglected diseases, which would also include depression and chronic respiratory disease.

Eighty-five per cent of debilitating illness in the world is caused by the ten most common diseases.

Landray said drug trials had become overly complicated and “hideously” expensive, and were failing to deliver effective, affordable drugs for patients.

Testing a drug typically costs more than a billion dollars and takes an average of

Synairgen - 2 Jun '20 - 06:56
0 56 10
Charts
Intraday chart. Click to open a chart window 6 Month chart. Click to open a chart window
Long Term Chart
2 Year chart. Click to open a chart window
Fundamental Data
Name Synairgen Plc Sector PHARMACEUTICALS & BIOTECHNOLOGY
Mkt.Sector ASM6 Mkt.Segment AMSM Turnover - Profit -17.73
Norm EPS -9.46 PE Ratio - Market cap 400 NMS -
News
19/01/2022 14:05 UKREG Synairgen plc Holding(s) in Company
12/01/2022 11:53 UKREG Synairgen plc Holding(s) in Company
07/01/2022 17:24 UKREG Synairgen plc Holding(s) in Company
06/01/2022 11:59 RNSNON Synairgen plc Synairgen announces partnership with Ashfield

A safe haven for all reasonable SNG shareholders. Please find a few useful links below.

The latest presentation from Lord Marsden on 28/01/21

https://youtu.be/nhFqeW6sIXg

Link to the Sharesoc presentation on 18th November
https://www.sharesoc.org/seminar/sharesoc-webinar-with-synairgen-sng-18-november-2020/

A link to the Lancet paper describing the impressive Phase II Covid 19 trial
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext

The latest interview with RM on 21/10/20
https://youtu.be/BFFo7fhk-zM

The link below is for anyone who wants to try to access SNG001 via the MAP!
https://www.clinigengroup.com/about-cliniport/

https://www.dhs.gov/sites/default/files/publications/20200901_mql_sars-cov-2.pdf

PlusOneCoin Top Posts
None yet...

Go to previous
62302
Jump to the specified articleSubmit
ohisay23 Jan '22 - 04:04 - 62300 of 62302
0 2 0
A predictably unpredictable virus..

https://www.cityam.com/new-covid-variant-is-spreading-like-wildfire-in-scandinavia-ba-2-stealth-mutation-now-half-of-all-coronavirus-cases-in-denmark-and-rapidly-pushing-omicron-aside/
Jam6223 Jan '22 - 08:07 - 62301 of 62302
0 0 0
If all systems are go, just 10% of the numbers in the tweet below will do us fine.

HTTPS://twitter.com/AIMdective/status/1484813435607130120?s=19
DAFAD23 Jan '22 - 08:11 - 62302 of 62302 Edit
0 0 0
Interesting from today's Sunday Times

Chronic Respiratory Disease!!

Rest of article behind paywall

Https://www.thetimes.co.uk/article/covid-blueprint-to-transform-new-drugs-for-millions-bbjpn2g69

Covid blueprint to transform new drugs for millions
Sir Martin Landray’s organisation will run low-cost, stripped-back clinical trials for the most common but often neglected diseases
Sir Martin Landray’s organisation will run low-cost, stripped-back clinical trials for the most common but often neglected diseases

The scientist who identified the first life-saving Covid drug will launch a project tomorrow to transform treatments for heart disease, dementia and arthritis.

Sir Martin Landray was the architect of the world-leading Recovery trial which identified the cheap steroid dexamethasone as an effective treatment.
His new not-for-profit organisation, Protas,

https://twitter.com/gggg2120/status/1484549659372752896

Public disclosure of inside information in accordance with article 17(1) of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)

AMSTERDAM, Jan. 20, 2022 (GLOBE NEWSWIRE) -- European FinTech IPO Company 1 B.V. (“EFIC1”), a special purpose acquisition company (SPAC) incorporated under the laws of the Netherlands and listed on Euronext Amsterdam (symbol: EFIC1 and EFICW), announced on 13 December 2021 in a joint press release with Azerion Holding B.V. (“Azerion”), a high-growth digital entertainment and media company, that they have reached an agreement to create a business combination (the “Business Combination”), pursuant to which EFIC1 will acquire 100% of the issued and outstanding share capital of Azerion. The rationale for the Business Combination, the envisaged structure of the transaction and additional information regarding Azerion and the Business Combination is further described in the aforementioned joint press release, the shareholder circular and the investor presentation, which are available on EFIC1’s website (www.efic1.com).

EFIC1 and Azerion will host an update call for the shareholders of EFIC1 on 21 January 2022 at 14:00 CET / 13:00 GMT via webcast to discuss the proposed transaction and Azerion’s new business update as announced by Azerion today (see https://www.azerion.com/press_releases/). The webcast will be accessible via EFIC1’s website: www.efic1.com, via the Shareholder Webcast tab on that website.

ABOUT AZERION

Azerion operates a high-growth, EBITDA profitable digital entertainment and media platform. It is a content-driven, technology and data company, serving consumers, digital publishers, advertisers and game creators globally. Azerion is engaged in a number of interrelated operating activities including providing technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers and game creators as well as developing, publishing, distributing and operating online social and casual games and digital content.

his from Plexal website, WHO IS THE LEADING ESPORT CO!!

Bidstack: immersed in an eSport cluster
Bidstack has changed the face of in-game advertising by delivering immersive, tailored ads within games across multiple platforms. Having achieved rapid growth since joining Plexal, it wanted to reach new clients.

Plexal connected Bidstack with a global technology company to help the startup make connections in the US market. Here East is also a growing cluster for eSports, and Plexal was able to introduce Bidstack to a leading eSport company that’s about to join the campus.

https://www.plexal.com/collaboration-stories/

Change of address probably linked to this paragraph from trading update

The management team has been working toward ensuring that we capitalise on the solid commercial opportunities ahead of us. The success of the media business, which has led to the announcement of today's transformational deal, will empower the product team to work on a number of technology-only and software-as-a-service deals that are expected to drive additional recurring revenue over and above the Group's advertising revenue.

https://www.plexal.com/

That Azerion deal could be bigger than we thought

https://about.ads.microsoft.com/en-gb/blog/post/january-2022/microsoft-

advertising-partner-awards-europe-finalists

Independent Partner of the Year
Awarded to an Elite Independent Partner that demonstrates effective engagement and true partnership with Microsoft Advertising to deliver success to their clients. This award recognises a partner that demonstrates a unified approach and advocates usage of Microsoft Advertising products and features, innovation, competitive differentiation, and customer value.

Adwise – Your Digital Brain
Azerion
CodeFuel – Perion Network
Marin Software
Push Group Ltd